Table 2.
Ongoing virotherapy clinical trials targeting glioma stem cells (GSCs).
| Virus family | Therapy type | Viral strain | Combination | Phase (O-III) | ClinicalTrials.gov Identifier |
|---|---|---|---|---|---|
| ADV | NSC vector oncolytic virus | BM-hMSC-DNX-2401 | I | NCT03896568 | |
| Reovirus | Oncolytic virus | Wild-type reovirus (reolysin) | Sargamostim (rGM-CSF) | I | NCT02444546 |
| Vaccinia virus | Oncolytic virus | TG6002 | 5-FC | I | NCT03294486 |
| ADV | Oncolytic virus | DNX-2440 | I | NCT03714334 | |
| HSV | Oncolytic virus | HSV G207 | Low dose radiation | I | NCT03911388 |
| HSV | Oncolytic virus | C134-HSV-1 | I | NCT03657576 | |
| ADV | Viral vector gene therapy | ADV/HSK-tk | Valacyclovir, SOC | I | NCT03596086 |
| ADV | Viral vector gene therapy | ADV/HSK-tk | Valacyclovir, SOC | I | NCT03603405 |
| ADV | Oncolytic virus | DNX-2401 | Pembrolizumab | II | NCT02798406 |
ADV, adenovirus; HSV, herpes simplex virus; rGM-CSF, recombinant granulocyte-macrophage colony-stimulating factor; 5-FC, flucytosine; SOC, standard of care.